-+ 0.00%
-+ 0.00%
-+ 0.00%

MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target

PUBT·07/15/2026 12:03:28
Listen to the news
MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target
  • MediciNova reached its 200-patient target enrollment in the NIH-funded SEANOBI-ALS expanded-access study of MN-166 (ibudilast) in ALS.
  • Program supplies MN-166 to ALS patients ineligible for ongoing randomized clinical trials under the ACT for ALS initiative.
  • Final patient follow-ups are projected to end in early 2027, with data analysis planned to support scientific presentations and peer-reviewed publications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150800PRIMZONEFULLFEED9761981) on July 15, 2026, and is solely responsible for the information contained therein.